Belgian AM service supplier Materialise launched Q2 2025 outcomes exhibiting modest income decline, however notable energy in its medical enterprise.
Within the second quarter of 2025, consolidated income declined by 5.8% to €64.83 million, in comparison with €68.80 million in Q2 2024. Nonetheless, the gross revenue margin improved to 58.3%, up from 57.0%, indicating higher value absorption and stronger pricing self-discipline. Adjusted EBIT dropped to €3.06 million (a 4.7% margin), down from €3.87 million (a 5.6% margin) within the earlier 12 months. Adjusted EBITDA eased to €8.29 million, in comparison with €9.19 million in Q2 2024.
The 5.8% decline was primarily on account of softness within the Manufacturing and Software program segments, pushed by geopolitical uncertainty and macroeconomic headwinds affecting industrial and business demand.
Regardless of decrease revenues, sturdy value management and improved product combine enabled Materialise to lift its gross revenue margin by 1.3 share factors year-over-year.
Adjusted EBIT improved sequentially—rising from €0.65 million in Q1 2025 to €3.06 million in Q2—although it remained beneath the extent seen in Q2 2024. Adjusted EBITDA declined reasonably, however margins stayed inside a wholesome vary.
Medical section enlargement
Materialise Medical delivered a robust 16.7% income improve to €32.85 million (up from €28.14 million in Q2 2024). Section Adjusted EBITDA rose to €10.73 million from €8.20 million, lifting the EBITDA margin to 32.7% from 29.1%. This displays sturdy demand for patient-specific implants and medical software program options.
Income declined 12.1% to €9.87 million, down from €11.23 million a 12 months earlier. Regardless of the drop, section EBITDA held regular at roughly €1.37 million, and the margin improved to 13.9%, up from 12.2%, because of efficient value administration.
Income within the Manufacturing section dropped 24.9% to €22.11 million, in comparison with €29.43 million final 12 months. The section reported a unfavourable Adjusted EBITDA of €0.81 million, reversing from a optimistic €2.42 million in Q2 2024. The section margin declined from 8.2% to –3.6%.
